Fig. 4.
XNC10-deficient 15/0 tumors elicit cellular antitumor immune responses. (A and B), Tadpoles were IP injected with 1×105 cells of either 15/0 WT, shScramble shXNC10 #4 or #7, cells were collected 7 days posttransplantation and each group pooled, immune-stained for CTX-APC, CD8-PE or MHC class II-PE and analyzed by flow cytometry. Percentage of (A) CTX−/CD8+ and (B) CTX-/Class II+ cells was determined. Top panels depict representative flow cytometry scatter plots of WT and shXNC10 #7. Three independent experiments with five animals per group were performed (C), Giemsa stain of cells isolated after 2 weeks of in vivo growth from WT collagen grafts (I and II) and XNC10-deficient tumor grafts (III and IV); tumor cells (Tu), macrophages (MΦ) and neutrophils (N).